Leucovorin

Leucovorin

SCHEMBL571902

Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc1)N2C=O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.80
LMNA P02545 1/20 0.62
MTHFD1 P11586 3/20 0.58
SOST Q9BQB4 1/20 0.57
MTHFD2 P13995 3/20 0.51
FPGS Q05932 2/20 0.51
ATIC P31939 2/20 0.51
TYMS P04818 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
AKR1B1 P15121 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
PTGS2 P35354 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucovorin SCHEMBL5132046 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Folinic Acid SCHEMBL29369091 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL21632556 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL4708750 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL8349 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL8350 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Levoleucovorin SCHEMBL571901 1.00 DHFR (0.80) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL9054117 0.99 DHFR (0.78) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL16207660 0.99 DHFR (0.78) DHFRLMNAMTHFD1SOSTMTHFD2
Leucovorin SCHEMBL9054183 0.99 DHFR (0.78) DHFRLMNAMTHFD1SOSTMTHFD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105999263-B Materials and methods for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases 第一三共欧洲有限公司 2021-06-29 CN disclosed
EP-3670539-A1 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES Daiichi Sankyo Europe GmbH (DE) 2020-06-24 EP disclosed
EP-3351558-B1 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES DAIICHI SANKYO EUROPE GMBH (DE) 2020-03-11 EP disclosed
EP-3351558-A2 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES Daiichi Sankyo Europe GmbH (DE) 2018-07-25 EP disclosed
US-9988462-B2 Material and methods for treating or preventing HER-3 associated diseases DAIICHI SANKYO EUROPE GMBH (DE) 2018-06-05 US disclosed
US-20180134805-A1 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES DAIICHI SANKYO EUROPE GMBH (DE) 2018-05-17 US disclosed
US-9803025-B2 Material and methods for treating or preventing HER-3 associated diseases AMGEN, INC. (US) 2017-10-31 US disclosed
EP-2896632-B1 Material and methods for treating or preventing HER-3 associated diseases DAIICHI SANKYO EUROPE GMBH (DE) 2017-10-25 EP disclosed
EP-2719708-B1 Material and methods for treating or preventing HER-3 associated diseases DAIICHI SANKYO EUROPE GMBH (DE) 2017-10-25 EP disclosed
US-20160222126-A1 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES U3 PHARMA GMBH (DE) 2016-08-04 US disclosed
US-9101760-B2 Material and methods for treating or preventing HER-3 associated diseases U3 PHARMA GMBH (DE) 2015-08-11 US disclosed
EP-2896632-A2 Material and methods for treating or preventing HER-3 associated diseases U3 Pharma GmbH (DE) 2015-07-22 EP disclosed
EP-2719708-A2 Material and methods for treating or preventing HER-3 associated diseases U3 Pharma GmbH (DE) 2014-04-16 EP disclosed
US-20140017166-A1 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES AMGEN, INC. (US) 2014-01-16 US disclosed
EP-2601220-A2 USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT U3 Pharma GmbH (DE) 2013-06-12 EP disclosed
EP-2499162-A2 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES U3 Pharma GmbH (DE) 2012-09-19 EP disclosed
US-20120156130-A1 USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT U3 PHARMA GMBH (DE) 2012-06-21 US disclosed
WO-2012018404-A2 USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT U3 PHARMA GMBH (DE) 2012-02-09 WO disclosed
US-20110229406-A1 Material and methods for treating or preventing HER-3 associated diseases U3 PHARMA GMBH (DE) 2011-09-22 US disclosed
WO-2011060206-A2 MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES U3 PHARMA GMBH (DE) 2011-05-19 WO disclosed